vs

Side-by-side financial comparison of INSTEEL INDUSTRIES INC (IIIN) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $159.9M, roughly 1.3× INSTEEL INDUSTRIES INC). INSTEEL INDUSTRIES INC runs the higher net margin — 4.7% vs -62.0%, a 66.8% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 23.3%). INSTEEL INDUSTRIES INC produced more free cash flow last quarter ($-2.2M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 12.0%).

Insteel Industries Inc is a leading U.S. manufacturer of steel reinforcing products including welded wire reinforcement and steel fibers. It primarily serves non-residential construction, infrastructure, and precast concrete segments across North America, delivering high-performance reinforcement solutions for various construction projects.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

IIIN vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.3× larger
RARE
$207.3M
$159.9M
IIIN
Growing faster (revenue YoY)
RARE
RARE
+2.6% gap
RARE
25.9%
23.3%
IIIN
Higher net margin
IIIN
IIIN
66.8% more per $
IIIN
4.7%
-62.0%
RARE
More free cash flow
IIIN
IIIN
$98.6M more FCF
IIIN
$-2.2M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
12.0%
IIIN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
IIIN
IIIN
RARE
RARE
Revenue
$159.9M
$207.3M
Net Profit
$7.6M
$-128.6M
Gross Margin
11.3%
Operating Margin
6.0%
-54.7%
Net Margin
4.7%
-62.0%
Revenue YoY
23.3%
25.9%
Net Profit YoY
602.4%
3.5%
EPS (diluted)
$0.39
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IIIN
IIIN
RARE
RARE
Q4 25
$159.9M
$207.3M
Q3 25
$177.4M
$159.9M
Q2 25
$179.9M
$166.5M
Q1 25
$160.7M
$139.3M
Q4 24
$129.7M
$164.6M
Q3 24
$134.3M
$139.5M
Q2 24
$145.8M
$147.0M
Q1 24
$127.4M
$108.8M
Net Profit
IIIN
IIIN
RARE
RARE
Q4 25
$7.6M
$-128.6M
Q3 25
$14.6M
$-180.4M
Q2 25
$15.2M
$-115.0M
Q1 25
$10.2M
$-151.1M
Q4 24
$1.1M
$-133.2M
Q3 24
$4.7M
$-133.5M
Q2 24
$6.6M
$-131.6M
Q1 24
$6.9M
$-170.7M
Gross Margin
IIIN
IIIN
RARE
RARE
Q4 25
11.3%
Q3 25
16.1%
Q2 25
17.1%
Q1 25
15.3%
Q4 24
7.3%
Q3 24
9.1%
Q2 24
10.6%
Q1 24
12.3%
Operating Margin
IIIN
IIIN
RARE
RARE
Q4 25
6.0%
-54.7%
Q3 25
10.8%
-106.9%
Q2 25
11.0%
-64.8%
Q1 25
8.3%
-102.6%
Q4 24
1.1%
-74.3%
Q3 24
4.5%
-94.6%
Q2 24
6.0%
-79.1%
Q1 24
7.0%
-151.9%
Net Margin
IIIN
IIIN
RARE
RARE
Q4 25
4.7%
-62.0%
Q3 25
8.2%
-112.8%
Q2 25
8.4%
-69.0%
Q1 25
6.4%
-108.5%
Q4 24
0.8%
-80.9%
Q3 24
3.5%
-95.7%
Q2 24
4.5%
-89.5%
Q1 24
5.4%
-156.8%
EPS (diluted)
IIIN
IIIN
RARE
RARE
Q4 25
$0.39
$-1.28
Q3 25
$0.74
$-1.81
Q2 25
$0.78
$-1.17
Q1 25
$0.52
$-1.57
Q4 24
$0.06
$-1.34
Q3 24
$0.24
$-1.40
Q2 24
$0.34
$-1.52
Q1 24
$0.35
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IIIN
IIIN
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$15.6M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$358.8M
$-80.0M
Total Assets
$456.1M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IIIN
IIIN
RARE
RARE
Q4 25
$15.6M
$421.0M
Q3 25
$38.6M
$202.5M
Q2 25
$53.7M
$176.3M
Q1 25
$28.4M
$127.1M
Q4 24
$36.0M
$174.0M
Q3 24
$111.5M
$150.6M
Q2 24
$97.7M
$480.7M
Q1 24
$83.9M
$112.3M
Stockholders' Equity
IIIN
IIIN
RARE
RARE
Q4 25
$358.8M
$-80.0M
Q3 25
$371.5M
$9.2M
Q2 25
$356.2M
$151.3M
Q1 25
$341.4M
$144.2M
Q4 24
$331.6M
$255.0M
Q3 24
$350.9M
$346.8M
Q2 24
$346.0M
$432.4M
Q1 24
$340.6M
$140.3M
Total Assets
IIIN
IIIN
RARE
RARE
Q4 25
$456.1M
$1.5B
Q3 25
$462.6M
$1.2B
Q2 25
$471.9M
$1.3B
Q1 25
$421.9M
$1.3B
Q4 24
$404.7M
$1.5B
Q3 24
$422.6M
$1.5B
Q2 24
$414.6M
$1.6B
Q1 24
$397.2M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IIIN
IIIN
RARE
RARE
Operating Cash FlowLast quarter
$-701.0K
$-99.8M
Free Cash FlowOCF − Capex
$-2.2M
$-100.8M
FCF MarginFCF / Revenue
-1.4%
-48.6%
Capex IntensityCapex / Revenue
0.9%
0.5%
Cash ConversionOCF / Net Profit
-0.09×
TTM Free Cash FlowTrailing 4 quarters
$439.0K
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IIIN
IIIN
RARE
RARE
Q4 25
$-701.0K
$-99.8M
Q3 25
$-17.0M
$-91.4M
Q2 25
$28.5M
$-108.3M
Q1 25
$-3.3M
$-166.5M
Q4 24
$19.0M
$-79.3M
Q3 24
$16.2M
$-67.0M
Q2 24
$18.8M
$-77.0M
Q1 24
$1.4M
$-190.7M
Free Cash Flow
IIIN
IIIN
RARE
RARE
Q4 25
$-2.2M
$-100.8M
Q3 25
$-18.7M
$-92.7M
Q2 25
$26.9M
$-110.7M
Q1 25
$-5.5M
$-167.8M
Q4 24
$16.3M
$-79.5M
Q3 24
$14.5M
$-68.6M
Q2 24
$15.5M
$-79.0M
Q1 24
$-580.0K
$-193.9M
FCF Margin
IIIN
IIIN
RARE
RARE
Q4 25
-1.4%
-48.6%
Q3 25
-10.6%
-58.0%
Q2 25
15.0%
-66.5%
Q1 25
-3.5%
-120.5%
Q4 24
12.6%
-48.3%
Q3 24
10.8%
-49.2%
Q2 24
10.7%
-53.7%
Q1 24
-0.5%
-178.2%
Capex Intensity
IIIN
IIIN
RARE
RARE
Q4 25
0.9%
0.5%
Q3 25
1.0%
0.8%
Q2 25
0.9%
1.5%
Q1 25
1.4%
1.0%
Q4 24
2.1%
0.1%
Q3 24
1.3%
1.2%
Q2 24
2.2%
1.4%
Q1 24
1.5%
3.0%
Cash Conversion
IIIN
IIIN
RARE
RARE
Q4 25
-0.09×
Q3 25
-1.17×
Q2 25
1.88×
Q1 25
-0.32×
Q4 24
17.56×
Q3 24
3.48×
Q2 24
2.86×
Q1 24
0.20×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IIIN
IIIN

Welded Wire Reinforcement$108.4M68%
PC Strand$51.6M32%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons